Thymagen vs Thymosin Alpha-1

Thymagen: Khavinson short peptide bioregulator targeting thymic function — Glu-Trp synthetic version. Typical dose 1,000-5,000 mcg. Thymosin Alpha-1: Thymic peptide with broad immunomodulatory activity, approved in over 35 countries. Typical dose 1000-1600 mcg. Both fall under the Bioregulators and Immune categories.

Stacking Thymagen with Thymosin Alpha-1 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Thymagen is typically dosed: Once daily (SubQ) or sublingual for Immune support. Thymosin Alpha-1 is typically dosed: Twice weekly (SubQ) for Immune modulation; Twice weekly for Hepatitis treatment (clinical protocol); Daily for initial phase, then twice weekly for Acute immune support.

Thymagen: Not FDA approved. Thymosin Alpha-1: Not FDA approved. Granted orphan drug designation for hepatocellular carcinoma and hepatitis B. Multiple clinical trials conducted but no NDA submitted.